NCT03606356View on ClinicalTrials.gov

Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 1, 2015

Primary Completion Date

April 1, 2018

Study Completion Date

April 1, 2018

Conditions
Migraine Disorders
Interventions
DRUG

Onabotulinum toxin A

Cranial Subcutaneous Injections

All Listed Sponsors
lead

Corfu Headache Clinic

OTHER

NCT03606356 - Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine | Biotech Hunter | Biotech Hunter